Items Tagged ‘unresectable’

July 19th, 2016

Loxo Oncology Receives Breakthrough Therapy Designation from U.S. Food and Drug Administration for LOXO-101


Loxo Oncology, Inc. (LOXO), a biopharmaceutical company innovating the development of highly selective medicines for patients with genetically defined cancers, announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation to LOXO-101, a selective inhibitor of tropomyosin receptor kinase (TRK), “for the treatment of unresectable or metastatic solid tumors with NTRK-fusion […]

View full entry

Tags: All Cancer Types, Breakthrough Therapy Designation, FDA. BTD, General, LOXO-101, metastatic solid tumors, News, TRK fusions, unresectable